RECRUITING

Novel Telemedicine-Delivered Prolonged Exposure Therapy for Treating PTSD in Individuals With OUD

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

Among individuals with opioid use disorder (OUD), posttraumatic stress disorder (PTSD) presents a significant clinical challenge. The prevalence of PTSD is substantially higher in individuals with OUD than in the general population, with nearly 90% reporting lifetime trauma exposure and 33% meeting diagnostic criteria for PTSD. The primary objective of this study is to evaluate the efficacy of a novel telemedicine-delivered prolonged exposure therapy protocol for improving PE attendance and reducing PTSD symptom severity in individuals with concurrent PTSD and OUD.

Official Title

Novel Telemedicine-Delivered Prolonged Exposure Therapy for Treating PTSD in Individuals With OUD

Quick Facts

Study Start:2024-05-15
Study Completion:2027-11-30
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT06288711

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * \>18 years old
  2. * Maintained on a stable methadone or buprenorphine dose for \>1 month prior to the study
  3. * Meet current DSM-5 posttraumatic stress disorder criteria based on the Clinician Administered PTSD Scale for DSM-5
  4. * Participants receiving psychotropic medications must be maintained on a stable dose for \>1 month prior to enrollment.
  1. * Current delusions or hallucinations, unstable bipolar disorder, imminent risk for suicide as assessed by the Mini International Neuropsychiatric Interview
  2. * Cognitive impairment as evidenced by scores \<22 on the Videoconference-based Mini Mental Status Examination (MMSE; Folstein, et al., 1975)
  3. * Enrolled in another ongoing evidence-based treatment for PTSD.
  4. * Pregnancy as verified by pregnancy test
  5. * No access to cellular service

Contacts and Locations

Study Contact

Kelly Peck, Ph.D.
CONTACT
8026569610
Kelly.Peck@uvm.edu

Study Locations (Sites)

University of Vemont
Burlington, Vermont, 05401
United States

Collaborators and Investigators

Sponsor: University of Vermont

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2024-05-15
Study Completion Date2027-11-30

Study Record Updates

Study Start Date2024-05-15
Study Completion Date2027-11-30

Terms related to this study

Additional Relevant MeSH Terms

  • Opioid Use Disorder
  • Posttraumatic Stress Disorder